Liberizin (Cytisinicline)

Cytisinicline, the active ingredient in Liberizin, is a nicotinic acetylcholine receptor agonist presented as an oral formulation for oral use. It is indicated for adult smokers seeking to quit and helps reduce nicotine withdrawal symptoms and cravings.

GNH USA supplies Liberizin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customers benefit from consistent batch release, comprehensive documentation, and responsive technical support throughout the supply chain.

Liberizin, a nicotinic acetylcholine receptor agonist, is used in the management of nicotine dependence and smoking cessation.

- Smoking cessation: assists adult smokers in quitting by reducing cravings, withdrawal discomfort, and the urge to smoke during the cessation process. - Nicotine dependence: supports patients with established nicotine addiction to gradually lower nicotine intake while minimizing relapse risk. - Relapse prevention: provides ongoing receptor modulation that helps maintain abstinence in individuals who have recently stopped smoking.

Cytisinicline may cause a range of adverse reactions, which are typically categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset that often resolves with continued therapy. - Headache: transient head pain that may improve with hydration or analgesics. - Insomnia: difficulty falling or staying asleep, especially during early treatment weeks. - Dry mouth: reduced salivation leading to a feeling of oral dryness.

Serious or Rare Side Effects: - Severe allergic reaction: signs include rash, itching, swelling, or difficulty breathing and requires immediate medical attention. - Mood alterations: emergence of depression, anxiety, or suicidal thoughts that should be reported promptly. - Cardiovascular events: rare occurrences of chest pain, palpitations, or hypertension that need urgent evaluation.

When prescribing Cytisinicline, clinicians should consider several safety measures to minimize risk.

- Cardiovascular assessment: evaluate history of heart disease before initiating therapy. - Psychiatric monitoring: observe for new or worsening depression, anxiety, or suicidal ideation. - Hepatic function: use caution in patients with moderate to severe liver impairment. - Concomitant nicotine products: avoid using other nicotine replacement therapies simultaneously. - Driving and machinery: advise patients to be cautious if dizziness or visual disturbances occur. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Cytisinicline can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): concurrent use may increase risk of hypertensive crisis. - Other nicotine replacement therapies: combined use can lead to excessive nicotinic stimulation and adverse effects. - Known hypersensitivity to cytisinicline or excipients: may trigger severe allergic reactions.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors: may raise cytisinicline plasma levels, requiring clinical observation. - Alcohol: can enhance central nervous system side effects such as dizziness or drowsiness.